217 related articles for article (PubMed ID: 23185373)
1. Pediatric response to second-line antiretroviral therapy in South Africa.
Zanoni BC; Sunpath H; Feeney ME
PLoS One; 2012; 7(11):e49591. PubMed ID: 23185373
[TBL] [Abstract][Full Text] [Related]
2. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
[TBL] [Abstract][Full Text] [Related]
3. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
[TBL] [Abstract][Full Text] [Related]
6. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
[TBL] [Abstract][Full Text] [Related]
7. Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load.
Kibalama Ssemambo P; Nalubega-Mboowa MG; Owora A; Serunjogi R; Kironde S; Nakabuye S; Ssozi F; Nannyonga M; Musoke P; Barlow-Mosha L
BMC Pediatr; 2021 Mar; 21(1):139. PubMed ID: 33752636
[TBL] [Abstract][Full Text] [Related]
8. Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
Salata RA; Grinsztejn B; Ritz J; Collier AC; Hogg E; Gross R; Godfrey C; Kumarasamy N; Kanyama C; Mellors JW; Wallis CL; Hughes MD;
AIDS Res Ther; 2023 Jan; 20(1):3. PubMed ID: 36604746
[TBL] [Abstract][Full Text] [Related]
9. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
10. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
12. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.
Moorhouse M; Maartens G; Venter WDF; Moosa MY; Steegen K; Jamaloodien K; Fox MP; Conradie F
J Acquir Immune Defic Syndr; 2019 Jan; 80(1):73-78. PubMed ID: 30334876
[TBL] [Abstract][Full Text] [Related]
13. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
14. The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.
Lippman SA; Mooney AC; Puren A; Hunt G; Grignon JS; Prach LM; Gilmore HJ; Truong HM; Barnhart S; Liegler T
BMC Infect Dis; 2020 Mar; 20(1):248. PubMed ID: 32216752
[TBL] [Abstract][Full Text] [Related]
15. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
[TBL] [Abstract][Full Text] [Related]
16. Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.
Tchounga BK; Charpentier C; Coffie PA; Dabis F; Descamps D; Eholie SP; Ekouevi DK
PLoS One; 2020; 15(8):e0236642. PubMed ID: 32756581
[TBL] [Abstract][Full Text] [Related]
17. It is time to consider third-line options in antiretroviral-experienced paediatric patients?
Zyl GU; Rabie H; Nuttall JJ; Cotton MF
J Int AIDS Soc; 2011 Nov; 14():55. PubMed ID: 22085598
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
19. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
Evans D; Hirasen K; Berhanu R; Malete G; Ive P; Spencer D; Badal-Faesen S; Sanne IM; Fox MP
AIDS Res Ther; 2018 Apr; 15(1):10. PubMed ID: 29636106
[TBL] [Abstract][Full Text] [Related]
20. Predictors of poor CD4 and weight recovery in HIV-infected children initiating ART in South Africa.
Zanoni BC; Phungula T; Zanoni HM; France H; Cook EF; Feeney ME
PLoS One; 2012; 7(3):e33611. PubMed ID: 22438965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
